John Wilkinson

    • Bavarian Nordic Acquires Two Commercial Vaccines from GlaxoSmithKline for €796 Million 

    • Silence Therapeutics Enters Collaboration With Mallinckrodt Worth up to $2 Billion 

    • Jazz Pharmaceuticals Acquisition of Redx Pharma's pan-RAF Inhibitor Program Valued up to $206 Million 

    • Mission Therapeutics Enters Collaboration Agreement with AbbVie 

    • Cooley Advises F-star on Collaborative Agreement with Denali Therapeutics 

    • Cooley Advises on the Admission to AIM of SalvaRx Group plc 

    • Immunocore Limited Series A $320 Million Financing 

    • Cooley Advises Immunocore on Largest European Private Life Sciences Financing on Record 

    • Bavarian Nordic Option and Licence Agreement With Bristol-Myers Squibb 

    • Bavarian Nordic MVA-BN Ebola Vaccine Licence to Janssen 

    • CRT Pioneer Fund Licence Agreements 

    • Meda: Rottapharm l Madaus Acquisition  

    • ALK-Abello Partnership Agreement with Abbott